{"identifier":"/us/usc/t21/s356d","title_num":"21","num":"§ 356d.","heading":"Coordination; task force and strategic plan","status":null,"guid":"ide4aabba8-ec7d-11e6-944b-93361b188886","source_credit":"(June 25, 1938, ch. 675, § 506D, as added Pub. L. 112–144, title X, § 1003, July 9, 2012, 126 Stat. 1103.)","seq_in_title":167,"parent_identifier":"/us/usc/t21/ch9/schV/ptA","ancestors":[{"identifier":"/us/usc/t21","level":"title","num":"Title 21—","heading":"FOOD AND DRUGS","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch9","level":"chapter","num":"CHAPTER 9—","heading":"FEDERAL FOOD, DRUG, AND COSMETIC ACT","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch9/schV","level":"subchapter","num":"SUBCHAPTER V—","heading":"DRUGS AND DEVICES","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch9/schV/ptA","level":"part","num":"Part A—","heading":"Drugs and Devices","status":null,"is_section":false}],"xml":"<section xmlns=\"http://xml.house.gov/schemas/uslm/1.0\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:dc=\"http://purl.org/dc/elements/1.1/\" xmlns:dcterms=\"http://purl.org/dc/terms/\" style=\"-uslm-lc:I80\" id=\"idae380a08-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d\"><num value=\"356d\">§ 356d.</num><heading> Coordination; task force and strategic plan</heading><subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae380a09-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a\"><num value=\"a\" class=\"bold\">(a)</num><heading class=\"bold\"> Task force and strategic plan</heading><paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae380a0a-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1\"><num value=\"1\" class=\"bold\">(1)</num><heading class=\"bold\"> In general</heading><subparagraph style=\"-uslm-lc:I18\" class=\"indent4 firstIndent-2\" id=\"idae380a0b-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/A\"><num value=\"A\" class=\"bold\">(A)</num><heading class=\"bold\"> Task force</heading><content><p style=\"-uslm-lc:I13\" class=\"indent2\">As soon as practicable after <date date=\"2012-07-09\">July 9, 2012</date>, the Secretary shall establish a task force to develop and implement a strategic plan for enhancing the Secretary’s response to preventing and mitigating drug shortages.</p>\n</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I18\" class=\"indent4 firstIndent-2\" id=\"idae380a0c-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/B\"><num value=\"B\" class=\"bold\">(B)</num><heading class=\"bold\"> Strategic plan</heading><chapeau>The strategic plan described in subparagraph (A) shall include—</chapeau><clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae380a0d-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/B/i\"><num value=\"i\">(i)</num><content> plans for enhanced interagency and intra-agency coordination, communication, and decisionmaking;</content>\n</clause>\n<clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae380a0e-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/B/ii\"><num value=\"ii\">(ii)</num><content> plans for ensuring that drug shortages are considered when the Secretary initiates a regulatory action that could precipitate a drug shortage or exacerbate an existing drug shortage;</content>\n</clause>\n<clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae380a0f-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/B/iii\"><num value=\"iii\">(iii)</num><content> plans for effective communication with outside stakeholders, including who the Secretary should alert about potential or actual drug shortages, how the communication should occur, and what types of information should be shared;</content>\n</clause>\n<clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae380a10-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/B/iv\"><num value=\"iv\">(iv)</num><content> plans for considering the impact of drug shortages on research and clinical trials; and</content>\n</clause>\n<clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae380a11-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/B/v\"><num value=\"v\">(v)</num><content> an examination of whether to establish a “qualified manufacturing partner program”, as described in subparagraph (C).</content>\n</clause>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I18\" class=\"indent4 firstIndent-2\" id=\"idae380a12-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/C\"><num value=\"C\" class=\"bold\">(C)</num><heading class=\"bold\"> Description of program</heading><chapeau>In conducting the examination of a “qualified manufacturing partner program” under subparagraph (B)(v), the Secretary—</chapeau><clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae380a13-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/C/i\"><num value=\"i\">(i)</num><chapeau> shall take into account that—</chapeau><subclause style=\"-uslm-lc:I16\" class=\"indent4\" id=\"idae380a14-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/C/i/I\"><num value=\"I\">(I)</num><content> a “qualified manufacturer”, for purposes of such program, would need to have the capability and capacity to supply products determined or anticipated to be in shortage; and</content>\n</subclause>\n<subclause style=\"-uslm-lc:I16\" class=\"indent4\" id=\"idae380a15-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/C/i/II\"><num value=\"II\">(II)</num><content> in examining the capability and capacity to supply products in shortage, the “qualified manufacturer” could have a site that manufactures a drug listed under <ref href=\"/us/usc/t21/s356e\">section 356e of this title</ref> or have the capacity to produce drugs in response to a shortage within a rapid timeframe; and</content>\n</subclause>\n</clause>\n<clause style=\"-uslm-lc:I14\" class=\"indent3\" id=\"idae380a16-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/C/ii\"><num value=\"ii\">(ii)</num><content> shall examine whether incentives are necessary to encourage the participation of “qualified manufacturers” in such a program.</content>\n</clause>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I18\" class=\"indent4 firstIndent-2\" id=\"idae380a17-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/1/D\"><num value=\"D\" class=\"bold\">(D)</num><heading class=\"bold\"> Consultation</heading><content><p style=\"-uslm-lc:I13\" class=\"indent2\">In carrying out this paragraph, the task force shall ensure consultation with the appropriate offices within the Food and Drug Administration, including the Office of the Commissioner, the Center for Drug Evaluation and Research, the Office of Regulatory Affairs, and employees within the Department of Health and Human Services with expertise regarding drug shortages. The Secretary shall engage external stakeholders and experts as appropriate.</p>\n</content>\n</subparagraph>\n</paragraph>\n<paragraph style=\"-uslm-lc:I79\" class=\"indent3 firstIndent-2\" id=\"idae380a18-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/2\"><num value=\"2\" class=\"bold\">(2)</num><heading class=\"bold\"> Timing</heading><chapeau>Not later than 1 year after <date date=\"2012-07-09\">July 9, 2012</date>, the task force shall—</chapeau><subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"idae380a19-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/2/A\"><num value=\"A\">(A)</num><content> publish the strategic plan described in paragraph (1); and</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I13\" class=\"indent2\" id=\"idae380a1a-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/a/2/B\"><num value=\"B\">(B)</num><content> submit such plan to Congress.</content>\n</subparagraph>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae380a1b-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/b\"><num value=\"b\" class=\"bold\">(b)</num><heading class=\"bold\"> Communication</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">The Secretary shall ensure that, prior to any enforcement action or issuance of a warning letter that the Secretary determines could reasonably be anticipated to lead to a meaningful disruption in the supply in the United States of a drug described under <ref href=\"/us/usc/t21/s356c/a\">section 356c(a) of this title</ref>, there is communication with the appropriate office of the Food and Drug Administration with expertise regarding drug shortages regarding whether the action or letter could cause, or exacerbate, a shortage of the drug.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae380a1c-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/c\"><num value=\"c\" class=\"bold\">(c)</num><heading class=\"bold\"> Action</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">If the Secretary determines, after the communication described in subsection (b), that an enforcement action or a warning letter could reasonably cause or exacerbate a shortage of a drug described under <ref href=\"/us/usc/t21/s356c/a\">section 356c(a) of this title</ref>, then the Secretary shall evaluate the risks associated with the impact of such shortage upon patients and those risks associated with the violation involved before taking such action or issuing such letter, unless there is imminent risk of serious adverse health consequences or death to humans.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae380a1d-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/d\"><num value=\"d\" class=\"bold\">(d)</num><heading class=\"bold\"> Reporting by other entities</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">The Secretary shall identify or establish a mechanism by which health care providers and other third-party organizations may report to the Secretary evidence of a drug shortage.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae380a1e-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/e\"><num value=\"e\" class=\"bold\">(e)</num><heading class=\"bold\"> Review and construction</heading><chapeau>No determination, finding, action, or omission of the Secretary under this section shall—</chapeau><paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"idae380a1f-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/e/1\"><num value=\"1\">(1)</num><content> be subject to judicial review; or</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"idae380a20-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/e/2\"><num value=\"2\">(2)</num><content> be construed to establish a defense to an enforcement action by the Secretary.</content>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idae380a21-ec38-11e5-9fc5-818d616f3d7f\" identifier=\"/us/usc/t21/s356d/f\"><num value=\"f\" class=\"bold\">(f)</num><heading class=\"bold\"> Sunset</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">Subsections (a), (b), (c), and (e) shall cease to be effective on the date that is 5 years after <date date=\"2012-07-09\">July 9, 2012</date>.</p>\n</content>\n</subsection>\n<sourceCredit id=\"idae380a22-ec38-11e5-9fc5-818d616f3d7f\">(<ref href=\"/us/act/1938-06-25/ch675\">June 25, 1938, ch. 675</ref>, § 506D, as added <ref href=\"/us/pl/112/144/tX\">Pub. L. 112–144, title X</ref>, § 1003, <date date=\"2012-07-09\">July 9, 2012</date>, <ref href=\"/us/stat/126/1103\">126 Stat. 1103</ref>.)</sourceCredit>\n</section>","provision":null,"duplicates":[],"release":{"label":"114-321","currency_date":"2016-12-16","congress":114,"law_num":321,"excluded_laws":[],"update_num":null,"seq":88,"is_partial":false,"caveat":null,"titles_affected":["05","15","21","26","28","29","38","42","48"],"ingested_titles":[]},"served_from":{"label":"114-321","currency_date":"2016-12-16","congress":114,"law_num":321,"excluded_laws":[],"update_num":null,"seq":88,"is_partial":false,"caveat":null,"titles_affected":["05","15","21","26","28","29","38","42","48"],"ingested_titles":[]},"content_first_seen":{"label":"114-115","currency_date":"2015-12-28","congress":114,"law_num":115,"excluded_laws":[],"update_num":null,"seq":62,"is_partial":false,"caveat":null,"titles_affected":["02","07","08","10","15","20","21","23","25","26","29","31","40","42","47","49","50"],"ingested_titles":[]},"is_exact":true,"note":null}